Supernus has had some challenges of its own of late, ... SPN-820, although it recently claimed FDA approval – at the fourth attempt – for Parkinson's disease therapy Onapgo ...

Supernus has boosted its position in central nervous system therapies with a $400 million deal to acquire Adamas Pharma that will add two approved Parkinson's disease therapies to its stable. The ...

Get the annual and quarterly balance sheet of Phibro Animal Health Corporation (PAHC) including details of assets, liabilities and shareholders' equity.

See Supernus Pharmaceuticals, Inc. (SUPN) Environment, Social and Governance Ratings to help you in your stock buying decisions.

Strategic actions by Supernus, Teva, Incyte, and BioNTech highlight growing momentum in advancing clinical-stage therapies and precision medicine for high-burden diseases. Lilly Launches Full Zepbound ...